- Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, as part of its $23 billion US infrastructure investment.
- The facility will expand Novartis’ capacity to produce precision radioligand therapies and strengthen its US supply network pending FDA approval for commercial manufacturing.
Novartis has announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California. The new site is part of the company’s previously announced $23 billion investment in US infrastructure over the next five years.
The facility, which has been filed with the US Food and Drug Administration (FDA) as an additional point of supply, will begin commercial manufacturing once approved. The Carlsbad site enhances Novartis’ ability to meet growing demand for radioligand therapies, a precision medicine that delivers targeted radiation directly to tumours while limiting exposure to surrounding healthy tissue.
“At Novartis, we tackle the toughest challenges in medicine by doing what’s never been done before for patients. Radioligand therapy is a breakthrough we’ve unlocked at scale, made possible by reimagining how innovation reaches patients.”
Vas Narasimhan, CEO of Novartis
The Carlsbad site is Novartis’ third RLT manufacturing facility in the US, reinforcing its global leadership in radioligand development, production, and delivery. The facility is designed to support existing FDA-approved RLT products and accommodate future expansion.
The investment forms part of Novartis’ wider plan to expand its US presence, which includes new facilities in Florida and Texas, as well as site expansions in Durham, Indianapolis, and Millburn. The company also plans to establish a new biomedical research hub in San Diego. Across all initiatives, Novartis expects to invest nearly $50 billion in its US operations over the next five years.
